-
1
المؤلفون: Caiyun Nie, Huifang Lv, Yingjun Liu, Beibei Chen, Weifeng Xu, Jianzheng Wang, Xiaobing Chen
المصدر: Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Combination therapy, medicine.medical_treatment, efficacy, Gastroenterology, Stable Disease, Internal medicine, medicine, Clinical endpoint, Adverse effect, RC254-282, Original Research, sintilimab, business.industry, Incidence (epidemiology), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Retrospective cohort study, Immunotherapy, medicine.disease, gastric/gastroesophageal junction adenocarcinoma, Oncology, immunotherapy, business, Lauren classification, Progressive disease
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da1b1561446637b4307fa4a9caf19057
http://europepmc.org/articles/PMC8494388 -
2
المؤلفون: Zev A. Wainberg, Keun-Wook Lee, Inho Kim, Anwaar Saeed, Giovanni Gerardo Cardellino, Alexandra Carolina Teixeira, Daniel V.T. Catenacci, Raquel Guardeño, Christophe Borg, Siddhartha Mitra, Erika Hitre, Jin Li, Anghel Adrian Udrea, Yoon-Koo Kang, Kensei Yamaguchi, Yingsi Yang, Sang Cheul Oh, Shukui Qin, Peter C. Enzinger, Haci Mehmet Turk
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, medicine.drug_class, Phases of clinical research, Gastroesophageal Junction Adenocarcinoma, Placebo, Monoclonal antibody, Gastroenterology, Double blind, Oncology, A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 [Catenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., Kim I., Oh S. C. , Li J., Turk H. M. , et al., -FIGHT], Internal medicine, Fibroblast Growth Factor Receptor 2b, Medicine, business
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84cd51b695b646eaa8b082749dbaa24
http://hdl.handle.net/20.500.12645/29666 -
3
المؤلفون: Andres O. Soriano, Nicolas Penel, Hendrik-Tobias Arkenau, Lars Zender, Ling Gao, Rafael Santana-Davila, Joana M Oliveira, Roy S. Herbst, Jennifer L. Cultrera, Ian Chau, Samuel McNeely, Johanna C. Bendell, Christophe Le Tourneau, Emiliano Calvo, Charles S. Fuchs, David Ferry, Gu Mi
المصدر: Cancers, Vol 12, Iss 2985, p 2985 (2020)
Cancers
Volume 12
Issue 10مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, ramucirumab, Pembrolizumab, lcsh:RC254-282, Article, Ramucirumab, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Clinical endpoint, 030212 general & internal medicine, phase 1b, Adverse effect, Antitumor activity, business.industry, Cancer, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, gastric/gastroesophageal junction adenocarcinoma, Tolerability, 030220 oncology & carcinogenesis, Adenocarcinoma, pembrolizumab, business
وصف الملف: application/pdf
-
4
المؤلفون: Yulong Zheng, Xin Xu, Jiong Qian, Lin Shen, Haiping Jiang, Chenyu Mao, Bo Peng, Nong Xu, Shuyan Wang, Hui Zhou, Donglei Zhu, Cheng Xiao, Ning Li, Lisong Teng, Huan Wang
المصدر: BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Tumor mutation burden, Drug-Related Side Effects and Adverse Reactions, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma, Antibodies, Monoclonal, Humanized, Gastroenterology, lcsh:RC254-282, Severity of Illness Index, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Stomach Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Genetics, medicine, Humans, Adverse effect, Aged, business.industry, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Sintilimab, Progression-Free Survival, Oxaliplatin, Clinical trial, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, Gastric/gastroesophageal junction adenocarcinoma, Esophagogastric Junction, business, Progressive disease, medicine.drug, Research Article, Follow-Up Studies
-
5
المؤلفون: Keun-Wook Lee, Zev A. Wainberg, Yingsi Yang, Shukui Qin, Helen Collins, Haci Mehmet Turk, Siddhartha Mitra, Giovanni Gerardo Cardellino, Alexandra Carolina Teixeira, Yoon-Koo Kang, Sang Cheul Oh, Daniel V.T. Catenacci, Kensei Yamaguchi, Raquel Guardeño, Jin Li, Peter C. Enzinger
المساهمون: TÜRK, HACI MEHMET
المصدر: Journal of Clinical Oncology. 39:160-160
مصطلحات موضوعية: Cancer Research, medicine.drug_class, business.industry, First line, Phases of clinical research, Gastroesophageal Junction Adenocarcinoma, Pharmacology, Placebo, Monoclonal antibody, Double blind, Wainberg Z. A. , Enzinger P. C. , Kang Y., Yamaguchi K., Qin Shukui Q. S. , Lee K., Oh S. C. , Li Jin L. J. , TÜRK H. M. , Teixeira A. C. , et al., -Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, business, 030215 immunology
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dfff608f3c1c9cd07f54b7554dd6501
https://doi.org/10.1200/jco.2021.39.3_suppl.160
Find this article in full text from Springer Verlag.